Ash Access Technology completes patient enrollment in Zuragen trial
The pivotal trial was designed to evaluate the efficacy and safety of Zuragen for the prevention and treatment of catheter-related bloodstream infection (CRBSI) in end-stage renal disease patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.